OptiNose

OptiNose — Q1 2022 Earnings Presentation

14 slides from OptiNose's earnings presentation, May 12, 2022

  1. Slide 1: Building a Leading ENT / Allergy Specialty Company Corporate Presentation

    Building a Leading ENT / Allergy Specialty Company Co r p o r a t e P r e s e n t a t i o n May 1 2 , 2 0 2 2

  2. Slide 2: Forward-Looking Statements

    2 Forward‐Looking Statements This presentation and our accompanying remarks contain “forward‐looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward‐looking statements for this

  3. Slide 3: Q1 2022 Performance

    Q1 2022 Performance

  4. Slide 4: Key Takeaways and Q1 2022 Highlights

    4 Key Takeaways and Q1 2022 Highlights Achieved Y/Y XHANCE Net Revenue Growth of 35% in Q1 2022 FY 2022 Revenue Guidance Implies Y/Y Growth of at least 22% Positive Top‐Line Results from ReOpen1 Reported in Q1 2022 +35% XHANCE Net Revenue Growth Q1 2022/Q1 2021 +21% XHANCE Net Revenue per TRx Growth

  5. Slide 5: XHANCE New and Total Prescriptions

    5 XHANCE New and Total Prescriptions XHANCE New Prescriptions increased 9% and Total Prescriptions increased 11% from Q1 2021 to Q1 2022 Estimated based on monthly prescription data from third parties and XHANCE preferred pharmacy network. The Market on this slide is defined as the sum of all intran

  6. Slide 6: XHANCE Market Share & Prescribers by Prescribing Frequency

    6 XHANCE Market Share & Prescribers by Prescribing Frequency The Market on this slide is defined as the sum of all intranasal steroid prescriptions written by physicians in the XHANCE target physician audience of approximately 21,000 physicians. Estimated based on monthly prescription data from thir

  7. Slide 7: Q1 2022 Financial Update

    Q1 2022 Financial Update

  8. Slide 8: Financial Review – First Quarter

    8 Financial Review – First Quarter 2021 XHANCE Net Revenue Increased 35% and Average Net Revenue per TRx Increased from $151 to $183 from Q1 2021 to Q1 2022 $11.0 $14.8 Q1 '21 Q1 '22 ($M) +35% $151 $183 Q1 '21 Q1 '22 +21% Net Revenue Average Net Revenue per TRx

  9. Slide 9: Full Year 2022 Financial Guidance

    9 Full Year 2022 Financial Guidance  XHANCE Net Revenue ‒ Expected to be at least $90 million  XHANCE Average Net Revenue per Prescription ‒ FY 2022 expected to exceed $220; previously expected to exceed $210  Operating Expense (GAAP) ‒ Expected to be between $135 – $140 million; approximately $1

  10. Slide 10: Additional Phase 3b Clinical Trial Data Expected in Q2 22

    10 Additional Phase 3b Clinical Trial Data Expected in Q2 2022 Recruitment Completed July 2021 Recruitment Completed October 2021 Top‐line results presented in Q1 2022 Top‐line results expected in June 2022 

  11. Slide 11: Closing Remarks

    optinose_ ———— Closing Remarks

  12. Slide 12: Key Takeaways and Q1 2022 Highlights

    12 Key Takeaways and Q1 2022 Highlights Achieved Y/Y XHANCE Net Revenue Growth of 35% in Q1 2022 FY 2022 Revenue Guidance Implies Y/Y Growth of at least 22% Positive Top‐Line Results from ReOpen1 Reported in Q1 2022 +35% XHANCE Net Revenue Growth Q1 2022/Q1 2021 +21% XHANCE Net Revenue per TRx Growt

  13. Slide 13: Investor Relations – Optinose Investor Contact

    13 Investor Relations – NASDAQ: OPTN Optinose Investor Contact Jonathan Neely, VP, Investor Relations and Business Development 267‐521‐0531 [email protected] At 31 March 2022: – $91.4 million in cash – Long‐term debt: $130 million – 82.7 million common shares o/s – 15.7 million options, warrant

  14. Slide 14: Building a Leading ENT / Allergy Specialty Company Corporate Presentation

    Building a Leading ENT / Allergy Specialty Company Co r p o r a t e P r e s e n t a t i o n May 1 2 , 2 0 2 2

OptiNose — Q1 2022 Earnings Presentation on 6ix